— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models —

— In May 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico's Investigational New...